2. UroToday Home
  3. Tags

Clinically Localized Prostate Cancer Articles

Articles

  • Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer.

    African American (AA) men have the highest incidence and mortality rate from Prostate cancer (PCa) than any other racial/ethnic group. To date, PCa genomic studies have largely under-represented tumour samples from AA men.

    Published June 8, 2023

  • Determinants of Prostate Cancer-specific Survival After Radiation Therapy for Patients with Clinically Localized Prostate Cancer

    PURPOSE:

    Identifying pretreatment and posttreatment predictors of time to prostate cancer-specific death (PCSD) after external-beam radiation therapy (RT) was the subject of this study.

    PATIENTS AND METHODS:

    A Cox regression analysis was used to evaluate the ability of the pretreatment risk group to predict time to PCSD for 381 patients who underwent RT for clinically localized prostate cancer. Posttreatment factors analyzed for the 94 patients who experienced prostate-specific antigen (PSA) failure included the time to PSA failure, the posttreatment PSA doubling time (DT), and the timing of salvage hormonal therapy.

    RESULTS:

    Despite the median age of 73 years at diagnosis, 45% of patients with high-risk disease were estimated to die from prostate cancer within 10 years after RT compared with 0% (P =.004) and 6% (P =.05) for patients with low- or intermediate-risk disease, respectively. Predictors of time to PCSD after PSA failure included PSA DT (P =.01) and delayed use of hormonal therapy (P <or=.002). Nearly identical estimates of PCSD and all-cause death after PSA failure were noted for patients with a short PSA DT (ie, <or= 12 months).

    CONCLUSION:

    Prostate cancer was a major cause of death during the first decade after RT for patients with clinically localized but high-risk disease, and the cause of death for patients with a short PSA DT after RT was nearly always prostate cancer. These data provide evidence to propose the hypothesis that a short posttreatment PSA DT may serve as a possible surrogate for PCSD. Prospective validation is needed


    J Clin Oncol. 2002 Dec 1;20(23):4567-73.

    Author Information:

    D'Amico AV1, Cote K, Loffredo M, Renshaw AA, Schultz D.

    1 Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA 02215, USA. 

    Pub Med: https://www.ncbi.nlm.nih.gov/pubmed/12454114
    Published October 17, 2017

  • Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.

    Identifying the subset of patients with clinically localized prostate cancer (PCa) at the highest risk of recurrence remains challenging, and better prognostic markers are needed. Gleason score is the best predictor of PCa aggressiveness and prognosis.

    Published September 29, 2016

  • Focal Therapy Eligibility Determined by MRI/US Fusion Biopsy: Beyond the Abstract

    The Executive Summary of the new AUA/ASTRO/SUO Guidelines for Clinically Localized Prostate Cancer recognizes focal therapy as a selected management option that may be implemented in appropriately selected men. However, long term oncological efficacy remains unknown and limits the utility of these treatments in the face of better studied treatment modalities.
    Published September 25, 2017

  • Focal therapy eligibility determined by MRI/US fusion biopsy.

    To assess focal therapy (FT) eligibility among men receiving multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy, with correlation to whole mount histology after radical prostatectomy (RP).
    Published August 31, 2017